HomeCompanyTechnologyPipelinePatientsInvestors & MediaCareersContact
Back to Investors & Media

May 27, 2018


May 27, 2018

Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer

May 27, 2018 – Lion TCR Pte Ltd, a clinical stage biotech pioneering T cell therapy against viral- related cancer, announced today they have raised US$ 20 million in its Series A financing round. The money raised is led primarily by undisclosed existing investors and other new investors such as ABC Capital and Westlake Ventures Capital.

The proceeds from this fundraising will be primarily used to advance its on-going clinical trials of its lead candidate LioCyx™ (personalized HBV specific TCR T cell therapy against HCC) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumours and clearance of chronic hepatitis B.

Hepatocellular carcinoma (HCC) has over 700,000 new cases every year, the world’s second deadliest cancer, of which 80% in Asia Pacific and 50% in China. Initial clinical trials of LioCyx™ for late stage HCC have produced encouraging results of good efficacy and very good safety profile. LioCyx™is developed by Lion TCR’s scientific founder, Prof. Antonio Bertoletti. The team and its collaborators in Singapore General Hospital have recently won the 2018 SingHealth Duke-NUS Research Award 1st Prize and the Best Abstract in EASL International Liver Congress 2018.

Dr. Victor Li, founder and CEO of Lion TCR, said “This finance is also a recognition of the potential, versatility, and uniqueness of Lion TCR’s novel viral specific TCR T cell technology platform and its products pipeline. It will allow us to accelerate the completion of Phase 1/2a clinical trial of LioCyx™ to treat relapsed HCC case post-liver transplantation and expand the therapy clinical trials for other indications of HCC. With a strong internal scientific team as well as collaborators from world renowned cancer research and medical centres in China, Singapore and Europe, Lion TCR continues to advance its pioneer position on engineered T cell therapy against viral related cancer and clearance of chronic hepatitis infection”.

For more information: The Wall Street Journal, PR Newswire

About Lion TCR

Lion TCR is a Singapore-based clinical stage biotech company focusing on development of engineered T-cell immunotherapy against viral-related cancer and chronic hepatitis B with manufacturing and clinical trial operations in China and Singapore. It is the world’s first to develop HBV-specific TCR T cell therapy against HCC.

Over one fifth of cancers in Asia are related to infection, primarily viral infection. For instance, nasopharyngeal carcinoma is 100% related to EBV infection and over 90% of HCC is related to HBV infection in China.

Lion TCR’s engineered T cell technology are exclusively licensed initially from the Agency for Science, Technology and Research (A*STAR), Singapore (TCR-T cell therapy developed by Prof. Antonio Bertoletti’s lab) and lately from Technical University of Munich (CAR-T cell therapy developed by Prof. Ulrike Protzer’s lab).